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Reinforcing endothelial junctions 
prevents microvessel permeability 
increase and tumor cell adhesion 
in microvessels in vivo
Bingmei M. Fu, Jinlin Yang, Bin Cai, Jie Fan, Lin Zhang & Min Zeng
Tumor cell adhesion to the microvessel wall is a critical step during tumor metastasis. Vascular 
endothelial growth factor (VEGF), a secretion of tumor cells, can increase microvessel permeability 
and tumor cell adhesion in the microvessel. To test the hypothesis that inhibiting permeability 
increase can reduce tumor cell adhesion, we used in vivo fluorescence microscopy to measure both 
microvessel permeability and adhesion rates of human mammary carcinoma MDA-MB-231 cells in 
post-capillary venules of rat mesentery under the treatment of VEGF and a cAMP analog, 8-bromo-
cAMP, which can decrease microvessel permeability. By immunostaining adherens junction proteins 
between endothelial cells forming the microvessel wall, we further investigated the structural 
mechanism by which cAMP abolishes VEGF-induced increase in microvessel permeability and tumor 
cell adhesion. Our results demonstrate that 1) Pretreatment of microvessels with cAMP can abolish 
VEGF-enhanced microvessel permeability and tumor cell adhesion; 2) Tumor cells prefer to adhere 
to the endothelial cell junctions instead of cell bodies; 3) VEGF increases microvessel permeability 
and tumor cell adhesion by compromising endothelial junctions while cAMP abolishes these effects 
of VEGF by reinforcing the junctions. These results suggest that strengthening the microvessel wall 
integrity can be a potential approach to inhibiting hematogenous tumor metastasis.
Increase in microvessel permeability is a critical step in many pathological processes including tumor 
metastasis1,2. Vascular endothelial growth factor (VEGF), a family of tumor angiogenic factors, has long 
been recognized to enhance microvascular permeability3–7 and increase tumor cell adhesion to endothe-
lium both in vivo and in vitro, under static and flow conditions8–10. Recent advances in the understanding 
of the molecular mechanisms of VEGF action have led to many anti-metastatic therapies, which include 
antibodies to block the binding of VEGF to its cellular receptors, small-molecule chemical inhibitors of 
the tyrosine kinase functions of the VEGF receptors, and antisense nucleic acids to interfere with cel-
lular production of VEGF4,8–14. However, anti-metastatic strategies targeting VEGF-mediated microves-
sel hyperpermeability by enhancing the barrier function of the microvessel wall have not been well 
developed15,16.
Previous studies have found that increased intracellular levels of adenosine 3′ , 5′ -cyclic monophos-
phate (cAMP) can block the inflammatory response in a variety of experimental models. Simultaneous 
stimulation of adenylate cyclase and phosphodiesterase inhibition to increase endothelial cAMP lev-
els was highly effective in inhibiting permeability increases induced by H2O2 in isolated rabbit lung17 
and in preventing capillary leakiness by lipopolysaccharide (LPS)-induced systemic inflammation in 
rats18. Previous studies on intact microvessels also confirmed that pretreatment with 8-bromo cAMP, a 
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cAMP analog, can abolish the microvessel hyperpermeability induced by ATP19, platelet-activating factor 
(PAF)20, bradykinin21 and VEGF22,23.
The cleft between adjacent endothelial cells is widely believed to be the principal pathway for water 
and hydrophilic solute transport through the microvessel wall under normal physiological conditions24. 
Inside the interendothelial cleft, junctions appear as discrete sites of fusion between the outer plasma 
membrane of adjacent cells when visualized in ultra-thin section electron microscopy. They create an 
intercellular barrier for material transport across the microvessel wall and can be regulated by response 
to physiological and tissue-specific requirements25. Using cell monolayers, many in vitro studies have 
showed that cAMP induces decreased paracellular permeability by a mechanism correlated to an increase 
in the number of junction strands or complexity26–32. To investigate the structural mechanism by which 
elevated intracellular cAMP levels regulate microvessel permeability in vivo, Adamson et al.33 quantified 
the number of junction strands in the interendothelial cleft from the same frog mesenteric microvessel 
on which permeability was determined33. Their study revealed that enhancement of intracellular cAMP 
levels decreases microvessel permeability by inducing an increase in the number of junction strands.
The structural mechanisms which have been studied to increase microvessel permeability by VEGF, 
inflammatory mediators and physical stimuli involve the formation of gaps between adjacent endothe-
lial cells in venular microvessels, vesiculo-vacuolar organelles (VVOs) pathways, transcellular pores and 
fenestra34. For transient increase in microvessel permeability induced by VEGF, Fu and Shen5 suggested 
that the most likely structural changes would be a ~2.5-fold increase in the width of the cleft between 
endothelial cells forming the microvessel wall and partial degradation of endothelial surface glycocalyx. 
By combining a mathematical model with the permeability measurement on frog mesenteric microves-
sels, Fu et al.22 also predicted that the inhibitory effect of cAMP on VEGF-induced microvessel hyper-
permeability is to generate more junction strands in the interendothelial cleft.
Therefore, on the basis of the previous studies on VEGF and cAMP effects on the microvessel per-
meability, the first aim of this study was to confirm that elevation of intraendothelial cAMP levels also 
abolishes/attenuates the transient increase in microvascular permeability by VEGF in intact rat microves-
sels. To do this, the microvessel permeability (P) to various sized solutes was measured in individually 
perfused post-capillary venules of rat mesentery10,22 under cAMP and VEGF treatments.
Our in vitro static study using cultured endothelial cell monolayers demonstrated that tumor cells pre-
fer to adhere to the junctions of endothelial cells instead of cell bodies9,35. It was found that tumor secre-
tion VEGF disrupts endothelial junction proteins to enhance the exposure of the underlying basement 
membrane to promote tumor cell adhesion to the adhesion molecules (e.g. laminins) in the extracellar 
matrix8,9,36. Thus, the second aim of this study was to investigate whether or not tumor cells prefer to 
adhere to the junctions of endothelial cells in intact microvessels under normal blood flow conditions. 
Consequently, the ultimate aim was to test the hypothesis that inhibiting VEGF-enhanced microvessel 
permeability by cAMP can also inhibit tumor cell adhesion to the microvessel wall; and this inhibi-
tion is through reinforcing the endothelial junctions. To accomplish these aims, in vivo fluorescence 
microscopy was employed to measure adhesion rates of human mammary carcinoma MDA-MB-231 in 
post-capillary venules of rat mesentery under flow and under the treatment of VEGF and cAMP; silver 
staining technique was used to identify the endothelial borders and adherent tumor cells; fluorescence 
immunostaining was applied to label adherens junction proteins between endothelial cells forming the 
microvessel wall under VEGF and cAMP treatments.
Results
Effect of cAMP on VEGF-enhanced Microvessel Permeability. Perfusion with solutions contain-
ing 2 mM 8-bromo-cAMP elicited a consistent decrease in apparent permeability P for all three mole-
cules, and abolished the transient increase induced by 1 nM VEGF. Figure 1 summarizes the results from a 
series of individual P measurements in post-capillary venules of rat mesentery. Figure 1A–C demonstrate 
microvessel permeability to a small solute sodium fluorescein (MW = 376, Psodium fluorescein), to an interme-
diate-sized solute α -lactalbumin (MW = 14,176, Pα-lactalbumin) and to a large solute BSA (MW = 67,000, 
PBSA), respectively. In the matched control group (shown in ○ ), after control and 20 min sham experi-
ments, Psodium fluorescein (Mean ± SE) in 5 vessels, measured at the peak of the response (~30 sec) to 1 nM 
VEGF, was 6.4 ± 0.74 × 10−5 cm/s, compared with a baseline P of 3.0 ± 0.24 × 10−5 cm/s, representing a 
2.2 ± 0.13-fold increase in the same vessel (p < 0.01).  In  the  test  group  (shown  in  •),  after 20 min pre-
treatment of 2 mM cAMP, Psodium fluorescein decreased from 3.4 ± 0.24 × 10−5 cm/s to 2.1 ± 0.18 × 10−5 cm/s 
(n = 8, p < 0.01), representing a mean ratio of 0.64 ± 0.051 to the baseline. At ~30 s after perfusion with 
1 nM VEGF/2 mM cAMP following 20 min cAMP pretreatment, Psodium fluorescein was 3.1 ± 0.18 × 10−5 cm/s; 
the mean ratio to the baseline was 0.92 ± 0.08 (p = 0.54). Pretreatment of 2 mM cAMP completely abol-
ished the VEGF-induced transient permeability increase.
Figure  1B,C show the results for Pα-lactalbumin and PBSA, respectively. In the matched control group 
(shown in ○ ), after control and 20 min sham experiments, Pα-lactalbumin and PBSA, measured at the peak 
of the response (~30 sec) to 1 nM VEGF, was 2.5 ± 0.54 and 0.37 ± 0.051 × 10−5 cm/s, compared with 
baseline P of 0.63 ± 0.051 and 0.052 ± 0.0041 × 10−5 cm/s, representing 3.9 ± 0.6-fold and 7.1 ± 0.8-fold 
increases, respectively (n = 5, p < 0.01). In the test group (shown in •), after 20 min treatment of 2 mM 
cAMP, Pα-lactalbumin decreased to 0.55 ± 0.073 (n = 8, p < 0.05) and PBSA to 0.65 ± 0.098 (n = 9, p < 0.05) 
of their baseline values, respectively. Same as for a small solute, pretreatment of 2 mM cAMP completely 
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abolished the VEGF-induced transient P increase for both intermediate and large sized solutes. At ~30 sec 
after perfusion with 1 nM VEGF/2 mM cAMP, Pα-lactalbumin and PBSA were 1.02 ± 0.11-fold (p = 0.86) and 
1.17 ± 0.11-fold (p = 0.24) that of their baseline values, respectively. Table  1 summarized the permea-
bility data under the control, cAMP and cAMP/VEGF treatment for all three solutes. In another group 
of 8 vessels, 20 min pretreatment of 4 mM cAMP reduced PBSA to 0.50 ± 0.05-fold (p = 0.03) that of its 
baseline value, which was not significantly different from that by 2 mM cAMP pretreatment (p = 0.17). 
However, following 20 min 4 mM cAMP pretreatment, at ~30 s after perfusion with 1 nM VEGF/4 mM 
cAMP, PBSA only returned to 0.77 ± 0.02-fold (p < 0.01) that of its baseline.
Figure 1. Effect of cAMP on VEGF-induced hyperpermeability in rat mesenteric microvessels for (A) 
sodium fluorescein, (B) α-lactalbumin and (C) bovine serum albumin (BSA). Mean ± SE P relative to 
baseline plotted as a function of time. In the matched control group (○ , BSA-BSA-VEGF), baseline P was 
first measured with Ringer perfusate containing 1% BSA, then P was measured in a sham experiment of 
reperfusion with control solution for ~20 min, and finally the P was measured under the treatment of 1 nM 
VEGF for ~5 min. In the test group (•, BSA-cAMP-VEGF), baseline P was first measured with perfusate 
containing 1% BSA, then P was measured in the test experiment of reperfusion with the same solution also 
containing 2 mM 8-bromo-cAMP for ~20 min, and finally the P was measured under the treatment of 1 nM 
VEGF and 2 mM 8-bromo-cAMP for ~5 min. *p < 0.05 compared with the baseline.
Solute n
Baseline (x 
10−5 cm/s)
cAMP (x 
10−5 cm/s) Ratio
cAMP/VEGF (x 
10−5 cm/s) Ratio
Sodium fluorescein 8 3.4 ± 0.23 2.1 ± 0.18 0.64 ± 0.051 3.1 ± 0.18 0.92 ± 0.08
α -lactalbumin 8 0.60 ± 0.04 0.38 ± 0.035 0.55 ± 0.073 0.65 ± 0.09 1.02 ± 0.11
BSA 9 0.052 ± 0.0047 0.034 ± 0.0049 0.66 ± 0.098 0.060 ± 0.0078 1.17 ± 0.11
Table 1.  Control and test values of apparent solute permeability induced by 2 mM 8-bromo-cAMP 
(after ~20 min treatment) and 2 mM 8-bromo-cAMP/1nMVEGF (after ~30 sec treatment) in the same 
vessels of rat mesentery. Values are means ± SE; n, number of vessels. VEGF, vascular endothelial growth 
factor. Ratio is that relative to the baseline value.
www.nature.com/scientificreports/
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Effect of cAMP on VEGF-enhanced Tumor Cell Adhesion to the Microvessel Wall. Adhesions 
of MDA-MB-231 cells in representative microvessels under various conditions are shown in Fig.  2A. 
Top panel images were taken at ~10 min and bottom images at ~60 min after perfusing tumor cells into 
individual microvessels. The perfusion velocity was ~1 mm/s, a mean blood flow velocity in this type of 
microvessels. Bright spots in these images represent adherent fluorescently-labeled tumor cells.
Figure 2B presents the time course of the amount of adherent tumor cells as indicated by fluorescence 
intensity in a vessel segment, under control (shown in ○ ), 1 nM VEGF treatment (•), pretreatment with 
2 mM cAMP and then 2 mM cAMP/1 nM VEGF treatment (▲ ) and pretreatment with 4 mM cAMP 
and then 4 mM cAMP/1 nM VEGF treatment (♦ ). Linear regression of data for intensity (cell adhesion 
amount) vs. time revealed that cell adhesion increased almost linearly with time from its baseline value 
starting at ~5 min under control and under all treatments (R2 > 0.96). The cell adhesion rate (the slope of 
the intensity vs. time curve) under 1 nM VEGF treatment was 2.8-fold that of the control value (p = 0.03), 
20 min pretreatment with 2 mM cAMP insignificantly reduced the adhesion rate to 2.5-fold that of the 
control value (p = 0.81 compared with VEGF alone). However, 20 min pretreatment with 4 mM cAMP 
completely abolished the VEGF-enhanced tumor cell adhesion (p = 0.88 compared with control).
Preferential Location of Tumor Cell Adhesion to the Microvessel Wall. The above results 
showed that VEGF increased microvessel permeability and tumor cell adhesion to the microvessel wall 
Figure 2. (A) Photomicrographs showing in vivo MDA-MB-231 cell adhesion to individually perfused 
microvessels in a control condition with 1%BSA-Ringer solution perfusate (first column), during treatment 
with 1 nM VEGF in the perfusate (second column), following 20 min pretreatment of the vessel with 
2 mM cAMP and then during treatment with 1 nM VEGF/2 mM cAMP in the perfusate (third column) 
and following 20 min pretreatment of the vessel with 4 mM cAMP and then during treatment with 1 nM 
VEGF/4 mM cAMP in the perfusate (fourth column). The top row is for those after ~10 min perfusion and 
the bottom row for those after ~60 min perfusion. The perfusion velocity was ~1 mm/s, which is the normal 
blood flow velocity in mesenteric post-capillary venules. (B) Adhesion of MDA-MB-231 cells as a function 
of time. Adhesion is shown in control conditions with 1% BSA-Ringer perfusate (○ ), during treatment with 
1 nM VEGF in the perfusate (•), following 20 min pretreatment of the vessel with 2 mM (▲ ) and 4 mM (♦ ) 
cAMP. *p < 0.001, #p < 0.05 compared with the control conditions. Values are means ± SE.
www.nature.com/scientificreports/
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and 4 mM cAMP could completely abolished these effects of VEGF. However, it is unclear how this was 
accomplished. To investigate the structural mechanism of inhibiting effects of cAMP on microvessel 
permeability and tumor cell adhesion, we first identified the adhesion location of tumor cells to the 
microvessel wall under flow. The endothelial cell boundaries were labeled by silver staining. Figure 3A–D 
demonstrate the photomicrographs of adherent MDA-MB-231 cells to the endothelia forming the 
microvessel wall after 60 min perfusion under control, treatment of VEGF, 20 min pretreatment of 4 mM 
cAMP and then cAMP/VEGF, and 20 min pretreatment of 4 mM cAMP and then cAMP, respectively. 
We grouped the locations of the adherent tumor cells into four categories: at the joint of two endothelial 
cells, at the joint of three (and four) cells, at the cell body and at uncertain locations such as at the edge 
of the vessel segment. Figure  3E compares the total number of adherent tumor cells per 5000 μ m2 of 
the mid-plane area in a vessel segment (~100–150 μ m long) under these conditions. After 20 min pre-
treatment of 4 mM cAMP, adherent tumor cells decreased from a control of 16.4 ± 2.6 to 9.3 ± 1.5 cells 
per 5000 μ m2 (p < 0.001). 1 nM VEGF increased adherent tumor cells to 33.6 ± 8.7 cells per 5000 μ m2 
Figure 3. Photomicrographs showing endothelial cell boundaries and adherent MDA-MB-231 cells after 
60 min perfusion from segments of individually perfused post-capillary venules in a control condition 
with 1% BSA-Ringer solution perfusate (A), during treatment with 1 nM VEGF in the perfusate (B), 
following 20 min pretreatment of the vessel with 4 mM cAMP and then during treatment with 4 mM 
cAMP/1 nM VEGF (C), and following 20 min pretreatment of the vessel with 4 mM cAMP and then 
during treatment with 4 mM cAMP alone (D). Endothelial cell borders were outlined with silver nitrate. 
The images were taken with a Nikon Fluor 40× /NA1.3, oil objective. Scale bar is 30 μ m. Comparison of 
adhesion of MDA-MB-231 tumor cells to the microvessel wall in a control condition with 1% BSA-Ringer 
solution perfusate (in 5 vessels, blue bar), during treatment with 1 nM VEGF in the perfusate (in 4 vessels, 
red bar), following 20 min pretreatment of the vessel with 4 mM cAMP and then during treatment with 
4 mM cAMP/1 nM VEGF (in 3 vessels, grey bar), and following 20 min pretreatment of the vessel with 
4 mM cAMP and then during treatment with 4 mM cAMP alone (in 4 vessels, green bar). (E) Number of 
total adherent tumor cells in vessel segments (F) Number of adherent tumor cells at junctions between two 
(Bi-joints), three and four (Tri/4 joints) endothelial cells, at endothelial cell bodies (Body) and at uncertain 
locations (Other) in vessel segments. *p < 0.001, compared with controls. Values are means ± SE.
www.nature.com/scientificreports/
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(p < 0.001). This increase can be inhibited by 20 min pretreatment of 4 mM cAMP, under which the 
number of adherent tumor cells was 18.7 ± 5.4 cells per 5000 μ m2, comparable to the control (p = 0.51). 
Out of these adherent tumor cells, Fig. 3F shows that the percentages of adherent tumor cells are 42.2%, 
37.1%, 47.9% and 46.3% to the bi-joints of endothelial cells; 51.3%, 51.5%, 41.2% and 42.1%, to the 
tri- and four joints; 2.7%, 3.4%, 3.9% and 4.9% to the cell body; and 3.8%, 8.0%, 7.0% and 6.7%, to the 
uncertain place, respectively, under control, cAMP, VEGF and cAMP-cAMP/VEGF treatments. More 
than 88% of the adherent tumor cells are at the endothelial junctions and less than 5% are on the cell 
bodies for all the cases. Almost all the effects of VEGF and cAMP on tumor cell adhesion are reflected 
from the amount of adherent tumor cells on endothelial junctions.
Effects of cAMP and VEGF on Endothelial Junction Proteins. The above observation that cAMP 
reduced VEGF-enhanced microvessel permeability and tumor cell adhesion to the joints of endothe-
lial cells forming the microvessel wall led us to the hypothesis that VEGF increases microvessel per-
meability by disrupting the integrity of the intercellular junctions while cAMP can reinforce them. 
To test this hypothesis, we quantified the endothelial adherens junction protein, vascular endothelial 
(VE)-cadherin, under control and cAMP/VEGF treatments. Figure  4A–D demonstrate the images for 
immunofluorescence-stained VE-cadherins at microvessel walls under control, after ~30 sec treatment 
of 1 nM VEGF, after 20 min treatment of 4 mM cAMP, and pretreatment of 4 mM cAMP for 20 min and 
~30 sec treatment of 1 nM VEGF/4 mM cAMP, respectively. Figure  4E shows the normalized intensity 
profiles of VE-cadherin distribution (along a 3 μ m perpendicular line to the cell-cell junction, shown in 
Fig. 4A). For each treatment, there was a control vessel prepared and imaged during the same time and 
the peak intensity value for the VE-cadherin labeling under the control was used to normalize the values 
under the treatment. Based on the kurtosis analysis, after 20 min treatment of 4 mM cAMP (green line), 
the intensity value of VE-cadherin labeling near the inter-endothelial joints is significantly higher than 
that of the control (blue line) (p = 0.04), the VE-cadherin labeling under acute treatment of 1 nM VEGF 
(red line) has a lower intensity value than that of the control (p = 0.006), while the VE-cadherin intensity 
Figure 4. Vascular endothelial (VE)-cadherin distribution in perfused microvessels. (A) In control 
vessels with 1% BSA-Ringer solution perfusate, the VE-cadherin label appeared as a continuous and 
smooth band; (B) in VEGF-treated vessels near the peak of the permeability response, the VE-cadherin 
label was nonuniform and discontinuous in some regions; (C) in cAMP-treated vessels, the VE-cadherin 
label was continuous, appeared in spikes and more intense compared with that in control vessels; (D) in 
vessels pretreated with cAMP, the VEGF treatment did not induce visible changes in the VE-cadherin label 
compared with control. (E) Normalized intensity profiles of VE-cadherin label distribution (along a 3 μ m 
perpendicular line to the cell-cell junction, shown in A). For each treatment, there was a control vessel 
prepared and imaged during the same time. The peak intensity of the VE-cadherin label from the control 
vessel was used to normalized that in the treated vessel. n = 80 measured profiles from about 20 cell pairs 
for each vessel. n = 640 for the control group, n = 160 for the cAMP group, n = 240 for the VEGF group as 
well as the cAMP/VEGF group. *p < 0.05 compared with controls. Values are means ± SE.
www.nature.com/scientificreports/
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value is comparable to the control level under 20 min pretreatment of 4 mM cAMP and acute treatment 
of 1 nM VEGF (purple line) (p = 0.15). These results conform to the hypothesis that cAMP inhibits the 
VEGF-enhanced microvessel permeability and tumor cell adhesion by reinforcing endothelial junctions.
Discussion
cAMP is one of the few signaling molecules that in general improve endothelial barrier function. Elevation 
of endothelial cAMP appeared effective in reducing the permeability of endothelial cells both in vitro and 
in vivo15,17,26,27,29,37,38. The effect is fast and occurs both under basal conditions and stimulated states such 
as in ischemia-reperfusion injury39, and after exposure to inflammatory agents, e.g., histamine, thrombin, 
ATP, PAF, H2O2, bradykinin17,19,20,21,26,40,41. Its efficacy is independent of whether cAMP is elevated by 
activation of adenylate cyclase or by the inhibition of cAMP-degrading phospodiesterases26,28,31,38, which 
broadens possible therapeutic approaches15. To search for the barrier-improving agents that can protest 
against microvascular hyperpermeability during tumor growth and metastasis, the first aim of our study 
was to test the hypothesis that elevation of the intraendothelial cAMP levels also abolishes/attenuates the 
transient increase in microvascular permeability by a tumor angiogenic factor, VEGF, in intact microves-
sels. Our results shown in Fig. 1 for the microvessel permeability to small, intermediate and large sized 
solutes have conformed to our hypothesis. Figure 1A–C also show that the lines for permeability under 
cAMP/VEGF treatments are slightly lower than those under VEGF treatment in the later time after the 
transient increase by VEGF. This implies the stabilizing effect of cAMP on permeability.
Recent review by Sayner38 presented the current themes of cAMP signaling pathways that regulate 
endothelial barrier integrity. Endothelial barrier integrity is maintained by transmembrane cell adhesion 
molecules that anchor adjacent cells to each other as well as anchoring cells into the underlying matrix. 
To perform this adhesive function, adhesion molecules are tethered into the cortical actin cytoskeleton 
by adaptor molecules, such as α -, β -, and γ -catenin, plakoglobin, and α -actinin, which, together with 
p120, form junctional complexes42,43. Adherens junctions formed by VE-cadherins are the major junc-
tional barrier between adjacent endothelial cells lining the microvessel wall24,44. Tight junctions com-
prised of ZO-1,-2,-3, together with occludins and claudins, were also identified in endothelial cells25,45,46. 
Adherens junctions, along with tight junctions, create a regulated paracellular barrier to the movement 
of water and solutes between endothelial cells47,48 and determine the microvessel permeability to water 
and hydrophilic solutes. Many previous studies have found that cAMP caused activation of Rac1 via 
both protein kinase A and Epac-triggered activation of Rap1, in order to modulate endothelial barrier 
integrity of microvessels by reinforcing adherens and tight junctions21,49–51. Our immuno-fluorescence 
staining for VE-cadherins under cAMP treatment is consistent with this observation (Fig. 4C,E).
Via activation of endothelial receptors, followed by fluxes of calcium ions, nucleotides, phospholipids, 
and ionic second messengers, VEGF increases vascular permeability by inducing cytoskeleton tension 
and disrupting endothelial junction barriers8,9,52. Recent review by Bates53 further reported that VEGF 
activation of endothelial cells results in phosphorylation and disassembly of VE-cadherin. VEGF medi-
ates a dephosphorylation of VE-cadherin, which disassociates from src and Csk, a negative regulator of 
src, thus enabling src to be activated. Results shown in Fig.  4B,E for the reduced VE-cadherins at the 
endothelial junctions confirm that VEGF compromised endothelial junction integrity in microvessel 
walls. Although other structural changes induced by VEGF were also observed in different types of blood 
vessels and under various conditions, such as vesiculo-vacuolar organelles (VVOs) pathways, transcellular 
pores and fenestra34, the transient increase in the width of the interendothelial cleft predicted by Fu and 
Shen5 provided an alternative. By forming new junction strands with pretreatment of 8-bromo-cAMP, 
the reinforced barriers in the cleft may diminish the increase in its width by VEGF and thus prevent the 
increase in microvessel permeability22. That the pretreatment of cAMP led the VE-cadherin levels return 
to the control levels after VEGF treatment (Fig. 4D,E) is consistent with the prediction from Fu et al.22.
Tumor cell metastasis through blood circulation is a complex process and is one of the great chal-
lenges in cancer research as metastatic spread is responsible for ~90% of cancer-related mortality54. 
Tumor cell adhesion to the microvessel wall is one critical step in metastatic spread. Previous study on 
intact microvessels indicated that adhesion of tumor cells to microvessel walls degrades the endothelial 
surface glycocalyx, another important structural component maintaining endothelial integrity35,55. So far, 
there is no direct experimental investigation on the effect of either VEGF or cAMP on the endothelial 
surface glycocalyx. But VEGF is likely to degrade this surface glycocalyx to expose the adhesion mole-
cules of endothelium and those in the basement membrane surrounding the microvessel. Fan et al.9 in an 
in vitro study revealed that VEGF disrupts the tight and adherens junctions of endothelial monolayers, 
enabling the exposure of the underlying basement membrane and increasing the binding of adhesion 
molecules on the tumor cells to their ligands (e.g. laminins) in the extracellular matrix. That almost all 
the effects of VEGF and cAMP on tumor cell adhesion are reflected from the amount of adherent tumor 
cells on the endothelial junctions (Fig. 3) suggests that what was observed in Fan et al.9 in their in vitro 
study is also valid in intact microvessels under normal blood flow conditions.
To determine whether tumor cells prefer to adhere at the endothelial junctions rather than randomly 
adhere on the microvessel wall, using the same approach as in9,37,56, we first measured the length of 
endothelial junctions per unit area for the microvessel shown in Fig. 3, the averaged value of which is 
104.2 ± 7.4 mm/mm2 (from 40 vessel segments). This junction length is then expanded by half of the 
contact length (diameter) of an adherent tumor cell, 3 μ m; the band area is thus 31.3% ± 2.2% of the 
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total area. If tumor cells adhere randomly to the microvessel wall, the percentage of the adherent tumor 
cells to the junctions should be less than 37.9%, three standard deviation larger than the mean value. 
However, under control and all the treatments, the percentage of adherent tumor cells to the junctions 
(bi-, tri- and four endothelial cell joints) is over 88%, much greater than 37.9%, indicating a preferential 
adhesion rather than a random process.
As shown in Fig. 2, pretreatment with 2 mM cAMP could not diminish VEGF-enhanced tumor cell 
adhesion although it completely abolished VEGF-enhanced microvessel permeability (Fig. 1). However, 
pretreatment with 4 mM cAMP could abolish both VEGF-enhanced effects, and further reduced 
microvessel permeability to that lower than the control value after VEGF/cAMP treatment. Based on 
the predictions from a mathematical model for the interendothelial cleft with single and double junction 
strands22, we found that because there were additional junction strands formed with pretreatment of 
2 mM cAMP, the microvessel permeability could go back to the control due to a more tortuous pathway 
for the movement of substances in the interendothelial cleft. However, the increased width of the cleft 
by VEGF could not return to its baseline, resulting in more exposed basement membrane. In contrast, 
pretreatment of 4 mM cAMP could reinforce better junction barriers, which protect the width of the cleft 
from the increase by VEGF, and consequently abolish the VEGF-enhanced tumor cell adhesion.
By using the same single microvessel perfusion method, our previous study10 reported that pre-
treatment of tumor cells with an antibody blocking VEGF or an antibody blocking a specific integrin, 
and pretreatment of the microvessel with VEGF receptor inhibitor, or anti-integrin extracellular matrix 
ligand antibody, can reduce the tumor cell adhesion under both control and the VEGF treatment. These 
results suggested that the cell adhesion molecules at the tumor cells and at endothelium are required for 
tumor cell adhesion to the microvessel wall. However, the enhanced microvessel permeability by VEGF 
and the reduced permeability by cAMP affect the contact opportunity of tumor cells to the endothelium 
and indirectly affect the adhesion. Enhanced endothelial junctions by cAMP could compensate the dis-
rupted junctions by VEGF and abolish the increased tumor cell adhesion to the basement membrane of 
endothelium.
In addition to strengthening the endothelial barrier function, Bianco et al.57 discovered that 
8-Chloro-cyclic AMP, another cAMP analogue, can suppress tumor growth by inhibiting angiogenic 
growth factor production in human breast and colorectal cancer. That cAMP-induced decrease in VEGF 
generation of tumor cells may also reduce tumor cell adhesion to the microvessels and inhibit tumor 
metastasis.
In summary, our study on intact microvessels indicates that pretreatment of microvessels with cAMP 
can abolish VEGF-enhanced microvessel permeability and tumor cell adhesion through reinforcing 
endothelial junction integrity. These results can be applied to broaden the anti-metastatic therapies by 
employing many widely recognized anti-inflammatory agents targeting the endothelial barriers. In addi-
tion to the structural mechanism, the signaling mechanism by which cAMP abolishes VEGF induced 
increase in microvessel permeability and tumor cell adhesion remains to be investigated. An understand-
ing of this mechanism would also help us develop new anti-metastatic therapies targeting the signaling 
pathway of tumor cell adhesion to the microvessel wall.
Materials and Methods
Animal Preparation. All experiments were performed on female Sprague-Dawley rats (250–300 g, 
age 3–4 months), supplied by Hilltop Laboratory Animals (Scottsdale, PA, USA). The experimental 
methods were in accordance with the guidelines and regulations approved by the Institutional Animal 
Care and Use Committee at the City College of the City University of New York. The protocol number 
is 925. The methods used to prepare rat mesenteries, perfusate solutions and micropipettes for microp-
erfusion experiments have been described in detail elsewhere10,35,58. A brief outline of the methods was 
given below with emphasis on the special features of the present experiments. At the end of experiments 
the animals were euthanized with excess anesthetic. The thorax was opened to ensure death58.
Rats were first anaesthetized with pentobarbital sodium given subcutaneously. The initial dosage was 
65 mg/kg and additional 3 mg/dose was given as needed. After a rat was anesthetized, a midline surgical 
incision (2–3 cm) was made in the abdominal wall. The rat was then transferred to a tray and kept warm 
on a heating pad. The mesentery was gently taken out from the abdominal cavity and spread on a glass 
coverslip, which formed the base of the observation platform as previously described10,35. The upper 
surface of the mesentery was continuously superfused by a dripper with mammalian Ringer solution at 
35–37 °C, which was regulated by a controlled water bath and monitored regularly by a thermometer 
probe. The microvessels chosen for the study were straight non-branched post-capillary venules, with 
diameters of 30–50 μ m.
Solutions and Reagents. Mammalian Ringer solution was used for all dissections, perfusate and 
superfusate10,35. In addition, the perfusate into the microvessel lumen contained bovine serum albumin 
(BSA) at 10 mg/ml (1% BSA-Ringer solution). All chemicals in the Ringer solution, BSA, 8-bromo-cAMP, 
fluorescence labeled solutes and AgNO3 were purchased from Sigma-Aldrich (St. Louis, MO). Cell 
Tracker Green were purchased from Invitrogen (Eugene, OR). VEGF (human recombinant VEGF165) 
was from Peprotech (Rocky Hill, NJ). The goat anti-bodies against VE-cadherin were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA) and Alexa fluor 555 conjugated donkey anti-goat secondary 
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antibodies from Invitrogen. Sodium fluorescein was dissolved at 0.1 mg/ml, FITC-BSA at 0.75 mg/ml in 
1%BSA-Ringer. α -lactalbumin was labeled with FITC (mol wt 389.4) as in58. The final concentration of 
FITC-α -lactalbumin was 0.75 mg/ml in 1% BSA-Ringer. All of the solutions described above were made 
at the time when the experiment was performed and were discarded at the end of the day.
Cell Culture and Fluorescent Tagging. Human breast carcinoma (MDA-MB-231) cells were pur-
chased from ATCC (Manassas, VA) and cultured and labeled with Cell Tracker Orange (Invitrogen, 
Eugene, OR) as previously described. Concentration of cell suspension was adjusted for the final perfu-
sate ~4 million/ml in 1% BSA-Ringer solution. The cell survival rate was > 95% before perfusion, and 
> 90% after ∼ 1.5 h perfusion at a rate ~1 mm/s in perfusing micropipettes.
Measurement of Apparent Microvascular Solute Permeability P. Measurement of P was taken 
on the individual post-capillary venules under control, pretreatment with 8-bromo-cAMP and in the 
perfusate with cAMP and VEGF. The detailed method using θ pipette for P measurement was previously 
described in10,35,58. Briefly, when the solution with fluorescently labeled solutes was perfused into the ves-
sel and the vessel was exposed to a 495 nm wavelength light, the images were recorded simultaneously by 
a high-performance digital 12-bit CCD camera (SensiCam QE, Cooke Corp., Romulus, MI, USA) with a 
Super Fluor 20 × objective lens (NA = 0.75, Nikon). Then the P was determined off-line. The total fluo-
rescence intensity (I) in the lumen of a straight vessel and surrounding tissue was determined by image 
analysis software (Intracellular Imaging Inc., Cincinnati, OH). The measuring window was 300–500 μ m 
long and 100–200 μ m wide and was set at least 100 μ m from the cannulation site and from the base of the 
bifurcation to avoid solute contamination from the cannulation site and from the side arms. Permeability 
P was calculated by P = (1/Δ I0)(dI/dt)0(r/2), where Δ I0 was the step increase in fluorescence intensity 
in the measuring window when the perfused dye just filled up the vessel lumen, (dI/dt)0 was the initial 
rate of increase in fluorescence intensity after the dye filled the lumen and began to accumulate in the 
tissue, and r was the vessel radius.
MDA-MB-231 Cell Adhesion in Individually Perfused Microvessels. To measure the tumor cell 
adhesion rate, a single straight post-capillary venule (30–50 μ m diameter) was cannulated with a micro-
pipette (~20–30 μ m tip diameter, WPI Inc., Sarasota, FL) filled with 1% BSA-Ringer solution containing 
~4 million cells/ml. The venule was perfused at a flow velocity of ~1 mm/s, which is a mean blood flow 
velocity in the post-capillary venules of rat mesentery. The perfusion flow velocity was determined by the 
driving pressure and was calculated from the movement of a marker tumor cell35. The adhesion process 
was recorded at ~2 frames/s in a ~5 min interval for ~60 min in each experiment. A single experiment 
was carried out in one microvessel per animal. Since we used 20× /NA0.75 objective lens to observe 
the cell adhesion, which has a depth of light collection ~100 μ m10,59, the cells adhering at the top and 
bottom of the vessel can also be observed when we focus at the mid-plane of the vessel. Cell adhesion 
was represented by the total cells (the fluorescence intensity of total adherent cells) in a vessel segment 
(vessel diameter wide and 300–400 μ m long). In vitro calibration experiments demonstrated that the 
fluorescence intensity of the fluorescently-labeled cells is a linear function of the number of cells.
Determination of Tumor Cell Adhesion Locations by Silver Staining Boundaries of Endothelial 
Cells Forming Microvessel Walls. To determine the locations of adherent tumor cells on microves-
sel walls, at the end of 60 min perfusion of tumor cells under different treatments (3 to 5 vessels for each 
group), the microvessel with adherent tumor cells was recannulated, perfused with AgNO3 (0.2 g/100 ml) 
in aqueous solution for 10–20 s, and then perfused with 1% BSA-Ringer to delineate the endothelial 
boundaries10,60. The images of microvessels with adherent tumor cells and silver nitrate stained endothe-
lial cell (EC) boundaries were taken by an inverted microscope system with a 40× /NA1.3 oil objective. 
The locations of adherent tumor cells were identified and grouped into four categories: at the joints of 
two ECs, at the joints of three and four ECs, at the EC bodies and others (e.g. at boundaries of vessels).
Immuno-labeling VE-cadherin of Microvascular Endothelial Cell Junctions. In order to quan-
tify the microvascular EC junctions under various treatments (2 to 3 vessels for each group), we used 
fluorescently conjugated antibodies to label the VE-cadherin of EC junctions and used confocal micros-
copy for the three-dimensional scanning20. After being perfused with the treatment solution through a 
cannulated micropipette, the microvessel was fixed by superfusing the tissue with ice-cold 1% paraform-
aldehyde for 3–5 min. The animal was sacrificed by anesthetic overdosing. The tissue (~1 cm × 1 cm) 
surrounding the vessel was then dissected, rinsed with ice cold PBS, permeabilized and blocked. After 
incubated with primary goat antibodies against VE-cadherin (1:100) for overnight at 4 °C, the free anti-
bodies were washed away by PBS, the tissue was incubated with Alexa fluor 555 conjugated donkey 
anti-goat secondary antibodies (1:200) for 1 h at 4 °C. After washing away the unbounded antibodies, 
the tissue was mounted on a glass coverslip. A secured-seal spacer (Invitrogen, Eugene, OR) was used 
to surround the tissue and to make a well about 120 μ m deep between two coverslips to retain the 
three-dimensional structure of the vessels.
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Intravital and Confocal Microscopy. A Nikon Eclipse TE2000-E inverted fluorescent microscope 
was used to observe the mesentery. The tissue was observed with either transmitted white light from a 
light pipe suspended above the preparation or with fluorescent light from an illumination system (the 
monochromator with a xenon lamp FSM150Xe, Bentham Instrument Ltd., UK). The monochromator can 
generate the light of wavelength from 200 to 700 nm. The observation of fluorescently labeled tumor cells 
in microvessels and measurement of microvessel solute permeability were done by a high-performance 
digital 12-bit CCD camera (SensiCam QE) with a Super Fluor 20× objective lens (NA = 0.75, Nikon) 
and recorded by the InCyt ImTM imaging and analyzing system (Intracellular Imaging Inc., Cincinnati, 
OH, USA). The silver nitrate stained boundaries of ECs forming the microvessel wall and the adherent 
tumor cells were observed by a 40× oil objective lens (NA = 1.3, Nikon).
The detailed distribution of fluorescently labeled VE-cadherin of endothelial junctions were observed 
using 12-bit laser scanning confocal microscopy (LSCM, Zeiss LSM 510 Confocal Microscope System) 
with a 63× /NA1.4 objective lens20. The Images were separately collected from either the top (near lens) 
or bottom half of each vessel, forming a stack of images along the z-direction. The thickness of each 
image was 0.5 μ m. Stacks of 15–35 images were projected onto a single plane for VE-cadherin intensity 
analysis. The lateral resolution was 2048 × 2048 for a vessel segment of ~89 × 89 μ m. Four segments were 
collected for each vessel. The image stacks were analyzed with the public domain National Institutes of 
Health IMAGE J program. An intensity profile of the VE-cadherin label was measured perpendicularly 
to the EC border at the randomly selected locations for 5 EC pairs in each segment. Four readings along 
each border and total 80 readings for each vessel were obtained. For each treatment vessel, there was a 
control vessel collected at the same time. The mean maximum intensity of the VE-cadherin label in the 
control vessel was used to normalize the intensity profile for the treatment and control vessels.
Experimental Protocol. To test the role of cAMP on VEGF-induced microvessel hyperpermeabil-
ity, for each test solute, after making several control measurements when the washout side was filled 
with 1% BSA-Ringer and the dye side was filled with the same perfusate to which the test solute was 
added, we replaced the pipette by a new pipette with both washout and test sides containing 2 mM 
8-bromo-cAMP, which concentration was consistent with that used in37,22. After ~20 min pretreatment 
of 2 mM 8-bromo-cAMP, we finally replaced the pipette by another new pipette with both washout and 
test sides that contained 8-bromo-cAMP (2 mM) and 1 nM VEGF, which concentration was consistent 
with that used in22, 58. P was measured every 15–30 sec including both dye (5–15 sec) and washout perfu-
sion (10–15 sec). The alternating perfusion of dye and washout solutions lasted ~5 min. The protocol for 
the matched control groups was the same as for the test groups except using 1% BSA Ringer perfusates 
without 8-bromo-cAMP.
To test the role of cAMP on VEGF-induced tumor cell adhesion, we pretreated the vessel with 2 mM 
or 4 mM cAMP for 20 min before perfusing the vessel with tumor cells in 2 mM or 4 mM cAMP and 
1 nM VEGF in 1% BSA Ringer. We chose 1 nM VEGF because 1) it represents the secretion level of 
tumor cells observed after prolonged incubation; 2) it may reflect a local VEGF level in microvasculature 
near a solid tumor; and 3) it was shown to be an optimal dose that significantly increased tumor cell 
adhesion and endothelial permeability both in vitro and in vivo8, 10. 2 mM cAMP was used because it can 
significantly decrease microvessel permeability22, 37.
Analysis and Statistics. P measurements during the control period in a vessel were averaged to 
establish a single value for the baseline P. This value was then used as a reference for all subsequent 
measurements on that vessel. Because of the difference in the cell concentration, fluorescence labeling 
and vessel size for different experiments, in the cell adhesion measurement we defined a base intensity 
I0 for each vessel, which was an averaged value of 3 measurements in the first 5 min of cell perfusion. 
The time course of cell adhesion I(t) was normalized as ( )I t
I 0
. To present adhesion data at a specific time 
after 5 min, individual measurements were grouped with 5 min intervals at 10 min (6–10 min), 15 min 
(11–15 min), etc. Both results for permeability and cell adhesion are presented in mean ± SE unless 
specified otherwise.
Statistical significance of the treatment over time was tested with a nonparametric Wilcoxon signed-rank 
test applied to the averaged adhesion data. Mann-Whitney’s U test was applied to between-group data 
to test for adhesion differences at specific times. Significance was assumed for probability levels p < 5%.
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